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Familial hemophagocytic lymphohistiocytosis (FHL) is an autosomal recessive disease of early childhood charac-
terized by nonmalignant accumulation and multivisceral infiltration of activated T lymphocytes and histiocytes
(macrophages). Cytotoxic T and natural killer (NK) cell activity is markedly reduced or absent in these patients,
and mutations in a lytic granule constituent, perforin, were recently identified in a number of FHL individuals.
Here, we report a comprehensive survey of 34 additional patients with FHL for mutations in the coding region of
the perforin gene and the relative frequency of perforin mutations in FHL. Perforin mutations were identified in 7
of the 34 families investigated. Six children were homozygous for the mutations, and one patient was a compound
heterozygote. Four novel mutations were detected: one nonsense, two missense, and one deletion of one amino
acid. In four families, a previously reported mutation at codon 374, causing a premature stop codon, was identified,
and, therefore, this is the most common perforin mutation identified so far in FHL patients. We found perforin
mutations in 20% of all FHL patients investigated (7/34), with a somewhat higher prevalence, ∼30% (6/20), in
children whose parents originated from Turkey. No other correlation between the type of mutation and the phe-
notype of the patients was evident from the present study. Our combined results from mutational analysis of 34
families and linkage analysis of a subset of consanguineous families indicate that perforin mutations account for
20%–40% of the FHL cases and the FHL 1 locus on chromosome 9 for ∼10%, whereas the major part of the
FHL cases are caused by mutations in not-yet-identified genes.
Introduction
Familial hemophagocytic lymphohistiocytosis (FHL
[MIM 267700]) is a rare autosomal recessive disorder
of infancy and early childhood, characterized by fever,
hepatosplenomegaly, and pancytopenia, and with neu-
rological involvement of varying degrees commonly de-
veloping during the course of the disease (Janka 1983;
Henter et al. 1998). The histopathological hallmark is
Received November 16, 2000; accepted for publication January 2,
2001; electronically published February 6, 2001.
Address for correspondence and reprints: Dr. Jan-IngeHenter, Child-
hood Cancer Research Unit Q6:05, Department of Pediatric Hema-
tology and Oncology, Karolinska Hospital, S-171 76 Stockholm, Swe-
den. E-mail: jan-inge.henter@kbh.ki.se
 2001 by The American Society of Human Genetics. All rights reserved.
0002-9297/2001/6803-0005$02.00
an infiltration—in spleen, liver, bone marrow, lymph
nodes, and the central nervous system—of lymphocytes
and macrophages, the latter being frequently engaged in
hemophagocytosis (Janka 1983; Henter et al. 1998). Hy-
percytokinemia with elevated serum levels of inflam-
matory cytokines—such as tumor necrosis factor a, in-
terferon g, and interleukin (IL-6)—are striking features
of FHL and indicate an uncontrolled activation of T
lymphocytes and macrophages (Henter et al. 1991b; Fu-
jiwara et al. 1993; Imashuku et al. 1996). Without treat-
ment, the disease is inevitably fatal. However, with che-
motherapy (Henter et al. 1997) in combination with
bone marrow transplantation (BMT), the disease can be
cured in a large proportion of cases (Jabado et al. 1997;
Durken et al. 1999).
Cytotoxic T and natural killer (NK) cell activity is
consistently low or absent in FHL patients (Perez et al.
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Table 1
Perforin Primer Sequences Used for PCR Amplification and
Direct Sequencing
Region and Primer Sequencea Annealing Site
Exon 2:
F 5′-tgtgccctgataatctgtg-3′ 3171–3190
F 5′-TCCCAGTGGACACACAAAG-3′ 3449–3667
R 5′-gcagcctccaagtttga-3′ 3901–3917
Exon 3:
F 5′-tcctagttctgcccacttac-3′ 4886–4905
F 5′-tctcttctcgcAGTTTCCAT-3′ 4982–5001
R 5′-GGGTTCCAGGGTGTAGTCCA-3′ 5471–5480
F 5′-ACTGCCCTGCGCACCTG-3′ 5164–5180
F 5′-GCCTCCTTCCACCAAACCTA-3′ 5323–5340
R 5′-GGTTGTTATTGTCCCACACG-3′ 5811–5828
F 5′-GTCACCACCCAGGACTGCTG-3′ 5659–5678
F 5′-ATCCAAGCATGGGGCCTG-3′ 5719–5736
F 5′-ATGACCTCCTTGGCACCTGT-3′ 5927–5946
R 5′-ggctcccactgtgaga-3′ 6169–6184
a Primers located in introns are lowercase type, whereas
exonic primers are capitalized.
1984; Arico et al. 1988; Eife et al. 1989; Egeler et al.
1996) and also may be suppressed in first-degree rela-
tives (Sullivan et al. 1998). In patients in remission, this
defect in cellular cytotoxicity remains after chemother-
apeutic treatment and is restored only after successful
BMT. By means of homozygosity mapping, two loci for
FHL have been disclosed—on 9q21.3-22 (FHL1) and
10q21-22 (FHL2)—and later studies have provided ev-
idence for additional genetic heterogeneity (Dufourcq-
Lagelouse et al. 1999a; Ohadi et al. 1999; Graham et
al. 2000). Recently, the chromosome 10q21-22 locus
was shown to be the gene encoding perforin (Stepp et
al. 1999), an important mediator of cellular cytotox-
icity. The perforin gene is a simple gene organized in
only three exons, of which only exons 2 and 3 are trans-
lated (Lichtenheld and Podack 1989). Mutations in the
perforin gene were identified in eight unrelated patients
with FHL; cultured lymphocytes from affected patients
displayed defective cytotoxic activity, and immunos-
taining revealed little or no perforin in the granules of
the patients studied (Stepp et al. 1999). Perforin is se-
creted from cytotoxic T lymphocytes and NK cells upon
conjugation between effector and target cell, and, in the
presence of calcium, it is able to penetrate themembrane
of the target cell, where it polymerizes to form a cell
death–inducing pore (Lichtenheld and Podack 1989;
Tschopp and Nabholz 1990; Lowin et al. 1995). Pore
formation leads to destruction of target cells by osmotic
lysis and by allowing entrance to granzymes, which trig-
ger apoptosis (Darmon et al. 1995; Darmon and Bleack-
ley 1998). Previous studies in perforin-deficient mice
infected with lymphocytic choriomeningitis virus or
staphylococcal enterotoxin B have demonstrated an un-
controlled expansion of cytotoxic T cells and attendant
cytokine-driven mortality, similar to the phenotype ev-
ident in FHL, and a role for perforin in the homeostatic
regulation of CD8 lymphocytes thus was inferred
(Ka¨gi et al. 1999; Matloubian et al. 1999). The occur-
rence of perforin mutations in FHL provides further
evidence for the importance of perforin in the regulation
of homeostasis within the human immune system.
So far, perforin mutations have been described in
eight unrelated FHL patients (Stepp et al. 1999). In the
present study, we sought to determine the frequency and
type of mutations in the perforin gene by direct se-
quencing of DNA from a large set of well-defined fam-
ilies affected by FHL.
Patients and Methods
Patients
A total of 34 unrelated families, each with one or
several children affected with FHL—originating from
Sweden ( ), Sweden/Portugal ( ), Norwaynp 3 np 1
( ), Finland ( ), Iceland ( ), Germanynp 1 np 1 np 1
( ), Romania ( ), Yugoslavia ( ), Turkeynp 4 np 1 np 1
( ), and Egypt ( )—were investigated for thenp 20 np 1
presence of mutations in the perforin gene. In families
with more than one affected child, only one sibling was
investigated. The patients included either had a known
family history of FHL (at least two affected children in
the family) ( ) or fulfilled the diagnostic criterianp 17
for hemophagocytic lymphohistiocytosis developed by
the Histiocyte Society (Henter et al. 1991a) and, in ad-
dition, either had undergone BMT ( ) or had diednp 9
of their disease prior to BMT ( ). None of thesenp 8
families or individuals was included in the previous re-
port by Stepp et al. (1999). The study was approved by
the ethics committee at the Karolinska Hospital.
Mutation Analysis
Genomic DNA was isolated from peripheral blood
leukocytes or cultured fibroblasts by standard proce-
dures. The obtained sequences was compared to the pub-
lished sequence for perforin (Lichtenheld et al. 1988).
Note that, for codon 332 and 426, we found a sequence
that differed from this one in all individuals analyzed,
although it corresponds to the sequence for perforin re-
ported by Shinkai et al. (1989). Primers for amplification
of exon 2 and 3 and cycle sequencing are listed in table
1. For dye-labeled primer cycle sequencing, the forward
primers contained the 21M13 complement, and the
reverse primers contained the M13 complement. For all
primer pairs, the annealing temperature were set to
58C. Genomic DNA (100–200 ng) was amplified in 5
ml 10 # PCR buffer (Perkin Elmer), 4 ml MgCl2 (25
mM), 4 ml dNTP (1.25 mM), 0.5 ml each of forward
and reverse primer (10 mM), and 0.9 U of AmpliTaq
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Table 2
Mutations in the Perforin Gene
Mutation
Type and
Family
Protein-
Sequence
Alterationa
Nucleotide-
Sequence
Alteration Exon
Nonsense:
1 Trp374stop 1122 GrA 3
7 Trp374stop 1122 GrA 3
9b Tyr219stop 657 CrA 3
11 Trp374stop 1122 GrA 3
17 Trp374stop 1122 GrA 3
Missense:
3 Ile224asp 671 TrA 3
9b Val50met 148 GrA 2
Deletion:
33 Dlys285c 853–855 del AAG 3
a The Trp374stop mutation was initially reported by
Stepp et al. (1999).
b Compound heterozygote.
c D p deletion.
Gold (Perkin Elmer). PCR amplification conditions
were: 15 min at 96C, and then 30 s at 96C, 20 s at
annealing temperature, and 30 s at 72C for 40 cycles
and 2 min at 72C. The PCR products were analyzed
on agarose gels and then were cycle sequenced with the
ABI PRISM Big Dye Primer Cycle Sequencing Ready
Reaction Kit (Applied Biosystems). For the cycle se-
quencing the following conditions were used: 10 s at
96C, 5 s at 55C, and 1 min at 70C (20 cycles) and
then, 10 s at 96C and 1 min 70C (20 cycles). All PCRs
were performed on an MJ Research PTC-200 DNA En-
gine. The sequencing reactions were analyzed on an ABI
Genetic Analyzer 310 (Applied Biosystems).
Linkage Analysis
In selected consanguineous families, polymorphic mi-
crosatellite markers mapped to 9q21.3-22, (D9S922,
D9S1867, D9S152, D9S1812, D9S257, D9S1680, and
D9S283) and to the perforin gene on chromosome
10q21 (D10S537) were analyzed for homozygosity.
PCRs for the markers were carried out as single reactions
in 96-well plates, using standard protocols. All the for-
ward primers were fluorescently labeled. PCR reactions
for each marker were performed separately, with the
products being pooled prior to gel electrophoresis on an
ABI 377 (96 wells) (PE Applied Biosystems). Resulting
genotype data were analyzed using GENESCAN 2.1 and
GENOTYPER 2.0 software from ABI (PE Applied
Biosystems).
Results
Strategy Outline for Mutation Analysis
The translated exon 2 and exon 3 of the perforin gene,
but not the untranslated exon 1, were amplified and
sequenced in a total of 34 families. Primarily, one or
both parents were sequenced in each family. If a mu-
tation was detected, this was later confirmed in the af-
fected child. In some families, DNA from the parents
was unavailable or insufficient, and, instead, DNA from
an affected individual was sequenced. In three families,
the amount of DNA was restricted and insufficient,
probably because of fragmentation of the DNA, and,
therefore, we were able to sequence only ∼95% of the
perforin gene in these cases.
Perforin Mutations
Perforin mutations were found in seven families (ta-
bles 2 and 3). Among these families, four children orig-
inating from Turkey were homozygous for a truncating
mutation in exon 3: trp374rstop. This mutation has
been described elsewhere in two independent cases
(Stepp et al. 1999). One child from Turkey was a com-
pound heterozygote with a maternal truncating muta-
tion, tyr219rstop, in exon 3, and a paternal missense
mutation, val50rmet, in exon 2. One Swedish patient
from a consanguineous family was homozygous for a
missense mutation, ile224rasp, in exon 3. One 3-bp
deletion in exon 3, resulting in loss of the lys285 residue,
was found in one child from Turkey. None of these four
latter mutations has been described elsewhere.
The trp374rstop mutation, which also has been de-
scribed by Stepp et al. (1999) in two unrelated families
of Turkish origin, is the most frequent mutation in the
perforin gene reported so far. The location of the mu-
tation is within a cysteine-rich epidermal growth factor
(EGF) precursor-type domain, between amino acid res-
idues 356 and 386, that is conserved in human, mouse,
and rat (Lowin et al. 1995). This domain exhibits a high
degree of homology between perforin and the comple-
ment factors (Lichtenheld et al. 1988; Podack 1992).
The ile224rasp mutation found in a consanguineous
Swedish family was traced in heterozygous form in three
generations of unaffected relatives. This mutation was
not identified in either heterozygous or homozygous
form in any other sequenced allele, indicating that this
is a private mutation. The mutation is located within
the transmembrane region, which is important for pore
formation (Liu et al. 1995). In addition, this isoleucine
residue is conserved in human, mouse, and rat (Lowin
et al. 1995). The second missense mutation affects
val50rmet, which also is conserved in human, mouse,
and rat (Lowin et al. 1995).
The homozygous 3-bp in-frame deletion of a lysine
residue at codon 285 was found in a Turkish child, who
died before treatment was initiated (table 3). Unfortu-
nately, blood from the parents was not available for
analysis. Neither the missense mutations nor the in-
frame deletion were found in 40 independent internal
Table 3
Clinical Findings and Mutation Designation in Families with FHL and Perforin Mutations
Family and
Mutation
Country
of Origin
of Parents
Consanguinity/
Family Historya
Age at
Diagnosis
(Mo)
/Sexb Fever Splenomegaly Cytopeniac H/Hd Hemophagocytosise
Treatment
before BMT
(VP/Cs/CsA/HLH-94)f BMT Status/Outcome
Trp374stop:
1 Turkey / 2/M      VP/Cs/CsA No BMT, dead
7 Turkey / 1/F    NDg  VP/Cs No BMT, dead
11 Turkey / 39/M      HLH-94 BMT, alive and well
17 Turkey / 10/F      No treatment No BMT, dead
Ile224asp:
3 Sweden / 58/F      VP/Cs/CsA BMT, alive, mild retardation
Tyr219stop/Val50met:
9 Turkey / 4/M      HLH-94 No BMT, dead
K285:
33 Turkey / 3/F      No treatment No BMT, dead
NOTE.— p finding is present;  p finding is not present.
a Family history p at least two affected children in the family.
b M p male; F p female.
c Affecting 2 of 3 lineages in peripheral blood (hemoglobin !90 g/L; platelets !100 # 109/L; neutrophils !1.0 # 109/L).
d H/H p hypertriglyceridemia and/or hypofibrinogenemia (fasting triglycerides 2.0 mmol/L or 3 SD of the normal value for age, fibrinogen 1.5 g/L or 3 SD).
e Hemophagocytosis of bone marrow, spleen, or lymph nodes, with no evidence of malignancy.
f VP p etoposide (VP-16); Cs p Corticosteroids; CsA p Cyclosporin A; HLH-94 p the treatment protocol HLH-94 of the Histiocyte Society (Henter et al. 1997).
g ND p no data available.
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Table 4
Polymorphisms in the Perforin Gene
Codon
Sequence
Alteration Effect on Protein
Allele
Frequency
(%)
123 CGTrCAT Argininerhistidine 92.5/7.5
173 ACGrACA Threoninerthreonine 84/16
274 GCCrGCT Alanineralanine 88/12
300 CACrCAT Histidinerhistidine 40/60
control chromosomes from individuals not displaying
the FHL phenotype, and, thus, they were inferred to be
pathogenic.
Polymorphisms in the Perforin Gene
One rare polymorphism was detected at the protein
level in the perforin gene (table 4). arg123his was con-
sidered to be a polymorphism, since this amino acid
change was present in one healthy carrier of FHL, who
transmitted a mutation (trp374stop) from the other al-
lele to his child (family 17). Since the carrier did not
show any signs of the disease, arg123his does not cause
FHL. Moreover, the amino acid at codon 123 is not
conserved among human, mouse, and rat. Three addi-
tional polymorphic sites were identified that did not have
any effect on the coding sequence (table 4).
Linkage Analysis
To determine the relative frequency, in other genes, of
mutations that cause FHL, we used linkage analysis in
consanguineous cases of FHL. Of the 27 families in
which no perforin mutation was detected, 13 were con-
sanguineous families with material available for linkage
analysis. Polymorphic DNA markers were studied
within the perforin gene region—as well as within the
chromosome 9q21.3-22 region linked to FHL in some
families (Ohadi et al. 1999).
Of 12 families who were informative for the marker
within the perforin gene on chromosome 10, only two
were homozygous (data not shown). These two cases
were heterozygous for markers within the 9q21.3-22
region (data not shown) and might carry mutations in
the perforin gene that escaped detection by DNA se-
quencing of exon 2 and 3, and, therefore, ∼15%-20%
of the consanguineous families might also be linked to
the perforin gene. Taking into account the 20% with
detected perforin mutations, no more than 35%–40%
of the FHL cases would be caused by mutations in this
gene.
Only one out of nine informative cases was homo-
zygous for markers at the chromosome 9 locus (data not
shown). This case was heterozygous for the marker
within the perforin gene (data not shown). This single
case may carry a mutation in the FHL 1 locus on chro-
mosome 9. On the basis of this analysis, 150% of the
FHL cases would be caused by mutations neither in the
perforin gene or the unidentified gene at the chromosome
9 locus.
Discussion
The present work describes the relative frequency and
the mutational spectrum in the perforin gene in families
afflicted with FHL. We have located homozygous, path-
ogenic perforin alleles in six families and one compound
heterozygote in one family—identifying five different
mutations altogether, in a total of seven families, that
are predicted to affect the coding sequence and function
of the protein (fig. 1) (table 2 and 3). One mutation,
trp374rstop, seems to be particularly common. By com-
parison of the sequences of the four families in our study
who originate from Turkey and carry this mutation, we
tried to identify single-nucleotide polymorphisms that
would indicate a common founder for this mutation,
but no such polymorphic sites were found that could
elucidate if the mutation is due to a founder effect.
The ile224rasp mutation was identified through four
generations in a consanguineous Swedish family. The
location of the mutation is within a region, with a high
degree of conservation among human, mouse, and rat,
that encodes one of the transmembrane domains of per-
forin, and the mutation, therefore, is predicted to give
rise to a nonfunctional protein (Liu et al. 1995). Stepp
et al. (1999) described a mutation, arg225rtrp, in the
same region in a compound heterozygote. Cells from
this patient showed greatly reduced cytolytic activity,
and immunostaining revealed nearly complete absence
of perforin (Stepp et al. 1999). The in-frame deletion,
Dlys285, was not detected in any of the 40 analyzed
control chromosomes from individuals not displaying
the FHL phenotype, suggesting that this is not a poly-
morphism. However, the mutation corresponds to the
published mouse and rat sequences. Hence, the possi-
bility can not be excluded entirely that this is a rare
polymorphism. In addition, a total of four polymor-
phisms or sequence variants were identified.
Our mutational analysis detected mutations in the
perforin gene in ∼20% of the 34 FHL families. Inter-
estingly, all perforin mutations, except the ile224rasp
mutation, were detected in patients with parents who
originated from Turkey. Of the subset of families orig-
inating from Turkey, perforin mutations were, in fact,
detected in ∼30% (6/20). This could be due to the higher
prevalence of consanguineous marriages in this group,
but it can be speculated that perforin mutations in FHL
might be more common in certain geographical areas
or ethnic groups.
We found a limited spectrum of missense mutations,
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Figure 1 Schematic representation of the perforin gene, showing the localization of mutations in FHL. The three exons of the perforin
gene are represented by boxes, introns by lines. The coding region of the perforin gene comprises exon 2 and 3 and is indicated by coloured
boxes. In the upper part of the figure, mutations identified in the present study are indicated. The trp374rstop mutation, initially reported by
Stepp et al. (1999), was identified in four families (see table 2). The lower part represents previously described mutations in the perforin gene
(Stepp et al. 1999). The mutations have been grouped with regard to whether they are nonsense mutations, missense mutations, or deletions.
compared with those studied elsewhere (Stepp et al.
1999). It can be reasoned that a loss-of-function is sup-
ported if it involves an amino acid conserved among
human, mouse, and rat. However, not all of the pre-
viously described missense mutations involved con-
served amino acids, although patients harboring these
mutations have been shown to display substantially re-
duced expression of perforin protein (Stepp et al. 1999).
Further assessment of the expression and function of
the missense mutations is required to understand how
these mutations impair perforin activity.
Heterogeneity has been implied in FHL, and it is rea-
sonable to assume that other genetic defects, in addition
to perforin mutations, are involved in this disease (Du-
fourcq-Lagelouse et al. 1999a; Ohadi et al. 1999; Gra-
ham et al. 2000). Our data suggest that perforin mu-
tations might cause 20%–40% of the cases of FHL, if
both detected mutations (20%) and subjects with no
mutation who were homozygous for the perforin poly-
morphism (15%–20%) are added. Similarly, the chro-
mosome 9 gene can explain only ∼10% of cases of FHL,
whereas the remaining cases, 150%, would be caused
by mutations in other, undefined genes.
We have previously demonstrated that immune cells
obtained from FHL patients remain susceptible to apop-
tosis induced in vitro by Fas ligation or the chemo-
therapeutic drug etoposide (Fadeel et al. 1999). Hence,
these stimuli triggered normal activation of intracellular
caspases and externalization of the phagocytic ligand,
phosphatidylserine, suggesting that the Fas receptor and
the intracellular apoptotic signaling machinery remain
intact in these patients. However, spontaneous activa-
tion of caspase-3-like enzymes wasmarkedly suppressed
or absent in a number of patients with FHL prior to
the initiation of cytotoxic therapy (Fadeel et al. 1999).
On the basis of these observations, we reasoned that
FHLmight be associated with the lack of an endogenous
apoptosis trigger, such as Fas ligand or components of
the perforin/granzyme B system, rather than apoptosis
resistance per se. Indeed, perforin-gene mutations have
now been described in a subset of FHL patients (Stepp
et al. 1999; the present study). On the other hand, sev-
eral lines of evidence, some of which admittedly are
circumstantial, suggest that Fas ligand is a less likely
candidate gene for FHL. The human Fas ligand has been
mapped to chromosome 1q23 (Takahashi et al. 1994)
and, therefore, does not correspond to either of the
known FHL loci. Moreover, although serum levels of
soluble Fas ligand are enhanced in FHL patients, values
are normalized upon successful chemotherapeutic treat-
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ment (Hasegawa et al. 1998; Fadeel, unpublished ob-
servations), thus indicating that these changes are a sec-
ondary event, perhaps reflective of excessive immune
activation. Finally, using CD4 and CD8 cytotoxic
T lymphocytes derived from autoimmune lymphopro-
liferative syndrome patients, Yasukawa et al. (2000) re-
cently have provided evidence that granule exocytosis,
and not the Fas/Fas ligand system, is the main pathway
of cellular cytotoxicity in humans. At present, we there-
fore favor the involvement of mutations in genes en-
coding granzymes A and B—or other, as-yet-unidenti-
fied components of lytic granules—in the pathogenesis
of FHL in those individuals who do not display per-
forin-gene mutations.
We were unable to establish a correlation between
the different mutations in the perforin gene and the
clinical manifestations of FHL. For instance, the age at
diagnosis of patients with the trp374rstop mutation
varied between one month and three years. This sug-
gests that other factors are also of importance with
regard to onset of the disease; such factors may be in-
fections and immunization. Moreover, severe encepha-
lopathy may or may not develop in a patient with a
perforin mutation. It can therefore be speculated that
initiating infections that affect the CNS may be more
devastating to the brain than infections with other organ
affection. We were also unable, in this limited patient
material, to establish a correlation between the occur-
rence or absence of mutations in the perforin gene and
clinical manifestations. Similarly, in a recent study, nei-
ther clinical nor pathological manifestations of FHL dif-
fered between patients who displayed linkage to 10q21-
22 compared to those who did not (Dufourcq-Lagelouse
et al. 1999a). Again, these observations support the
notion that other putative genetic defects in non-10q21-
22 linked FHL target components of the same (perforin-
dependent) signaling pathway. However, subtle differ-
ences may exist—for instance, in the pattern of defective
cellular cytotoxicity—that would allow for the differ-
entiation of the different subtypes of FHL. Further stud-
ies clearly are needed in which a detailed assessment of
phenotypic features is performed and is compared to
the occurrence and type of perforin mutations. In ad-
dition, attention should be focused on the distinction
between FHL and other, related disorders of macro-
phage activation and immune deregulation, such as
Chediak-Higashi syndrome, X-linked lymphoprolifer-
ative disease, and Griscelli syndrome, for which the
causative genetic defects have been characterized (Du-
fourcq-Lagelouse et al. 1999b).
In conclusion, we have confirmed the occurrence of
mutations in the perforin gene in a large subset of FHL
patients. We found five different mutations in seven
families, four of which were not previously described.
However, the detailed mechanisms by which mutations
in the perforin gene result in the FHL phenotype still
need to be clarified to improve our understanding of
the pathogenesis of this fatal disease, and detection of
additional pathogenic gene alterations is warranted to
further facilitate carrier and prenatal diagnosis.
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